STOCK TITAN
  1. Home
  2. Sec-filings
  3. LNTH
  4. [ARS] Lantheus Holdings, Inc. SEC Filing

[ARS] Lantheus Holdings, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS

Rhea-AI Filing Summary

Analyzing...
ARS - Lantheus Holdings, Inc.

ARS Filing - Lantheus Holdings, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Lantheus Holdings, Inc. (LNTH)

Acceptance Date: 2026-03-20T16:19:25.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Lantheus Holding

NASDAQ:LNTH

View LNTH Stock Overview →

LNTH Rankings

#1392 Ranked by Market Cap
N/A Ranked by Dividends

LNTH Latest News

Mar 17, 2026
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
Mar 6, 2026
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
Mar 2, 2026
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
Feb 26, 2026
Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Feb 24, 2026
Lantheus to Present at March 2026 Investor Conferences

LNTH Latest SEC Filings

Mar 20, 2026
[DEF 14A] Lantheus Holdings, Inc. Definitive Proxy Statement
Mar 10, 2026
[PRE 14A] Lantheus Holdings, Inc. Preliminary Proxy Statement
Mar 9, 2026
[Form 4] Lantheus Holdings, Inc. Insider Trading Activity
Mar 9, 2026
[Form 4] Lantheus Holdings, Inc. Insider Trading Activity
Mar 9, 2026
[Form 4] Lantheus Holdings, Inc. Insider Trading Activity

LNTH Stock Data

5.04B
63.03M
Drug Manufacturers - Specialty & Generic
In Vitro & in Vivo Diagnostic Substances
Link
United States
NORTH BILLERICA